Invitrogen™ Human VEGF Receptor 3/FLT4 ELISA Kit

Description

Includes

Aluminium pouch(es) with a Microwell Plate coated with monoclonal antibody to human VEGF-R3/FLT-4
Biotin-Conjugate anti-human VEGF-R3/FLT-4 monoclonal antibody
Streptavidin-HRP
Human VEGF-R3/FLT-4 Standard lyophilized, 80ng/mL upon reconstitution
Sample Diluent
Assay Buffer Concentrate 20x (PBS with 1% Tween 20 and 10% BSA)
Wash Buffer Concentrate 20x (PBS with 1% Tween 20)
Substrate Solution (tetramethyl-benzidine)
Stop Solution (1M Phosphoric acid)
Blue-Dye
Green-Dye
Red-Dye
Adhesive Films

ELISA

The Human Vascular Endothelial Growth Factor Receptor 3/FLT4 (Hu VEGFR3) ELISA quantitates Hu VEGFR3 in human serum, plasma, buffered solution, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu VEGFR3. Principle of the method The Human VEGFR3 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Vascular endothelial growth factor is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Unlike VEGF, the related VEGFC stimulates the growth of lymphatic vessels through its specificl ymphatic endothelial receptor VEGFR-3. In 1998, Dumont showed that targeted inactivation of the VEGFR-3 gene in mice resulted in defective blood vessel development in early embryos. Vasculogenesis and angiogenesis occurred, but large vessels became abnormally organized with defective lumens, leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5. Thus, VEGFR3 has an essential role in the development of theembryonic cardiovascular system before the emergence of the lymphatic vessels.

Specifications

• Accession Number: P35916
• Assay Range: 0.6 to 40.0 ng/mL
• Assay Sensitivity: 0.03 ng/mL
• Conjugate: HRP
• Product Type: ELISA
• Sample Type: Plasma, Serum, Supernatant
• Target Species: Human
• For Use With (Application): ELISA
• For Use With (Equipment): Colorimetric Microplate Reader
• Gene ID (Entrez): 2324
• Gene Symbol: FLT-41,LMPH1A,PCL,VEGFR-3,VEGFR3,FLT4
• Interassay CV: 5%
• Intraassay CV: 5.7
• Kit Contents: Pre-coated 96 well plate, Standard, Sample Diluent, Assay Buffer concentrate, Biotinylated Detection Antibody, SAV-HRP, Wash Buffer, Chromogen, Stop Solution, Adhesive Plate Covers
• Label or Dye: HRP
• Quantity: 10 x 96 Tests
• Regulatory Status: RUO
• Sample Volume: Plasma 20 μL, Serum 20 μL, Supernatant 20 μL
• Storage Requirements: 2°C to 8°C
• Synonym: FLT-4, VEGF receptor 3, PCL
• Target: VEGF Receptor 3
• Test Time: 1 hrs 20 mins
• Total Assay Time: 3 hrs 30 mins

Safety and Handling

WARNING: Cancer and Reproductive Harm - www.P65Warnings.ca.gov